Loading
An ADC wearing a mask that only comes off inside the tumour, so it ignores the same protein on healthy tissue.
Probody platform (CytomX; praluzatamab ravtansine CD166, CX-2051 EpCAM with TOP1 payload showing responses in colorectal cancer in 2025) and protease-activated designs allow targeting of antigens that are also expressed at high levels on normal tissue (EGFR, EpCAM, CD71). Also 'tumour microenvironment-activated' linkers cleaved by extracellular proteases.
Peptide mask blocks antigen binding until cleaved by tumour-enriched proteases (MMPs, uPA, legumain).
Query for this technology: (TITLE:"conditionally active antibody-drug conjugate" OR ABSTRACT:"conditionally active antibody-drug conjugate" OR TITLE:"probody" OR ABSTRACT:"probody" OR TITLE:"masked antibody-drug conjugate" OR ABSTRACT:"masked antibody-drug conjugate"). Results are unfiltered search hits about Masked / conditionally active ADC, not a curated reading list.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Logic-gated therapeutics (AND, NOT gates) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Logic-gated therapeutics (AND, NOT gates), ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares DNA origami nanorobots and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.
Shares ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs, Antibody-drug conjugate (ADC) and the tag frontier.